EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2477	((562/465) or (562/471) or (514/683) or (546/339) or (514/277)).CCLS.	US-PGPUB; USPAT	OR	OFF	2007/09/27 06:07
L2	7	1 and phenylalkanoic and acid	US-PGPUB; USPAT	OR	OFF	2007/09/27 06:07

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\asdfanjiwer.str





chain nodes :
1 2 3 4 8 15 18 36 37 38 39 40 42
ring nodes :
9 10 11 12 13 14 20 21 22 23 24 25 27 28 29 30 31 32
ring/chain nodes :
19
chain bonds :
1-2 2-3 2-8 8-11 14-18 18-19 19-22 37-38 37-39 37-40
ring bonds :
9-10 9-14 10-11 11-12 12-13 13-14 20-21 20-25 21-22 22-23 23-24 24-25 27-28
27-32 28-29 29-30 30-31 31-32
exact/norm bonds :
2-8 8-11 14-18 18-19 19-22 20-21 21-22 22-23 23-24 37-38 37-39 37-40
normalized bonds :
1-2 2-3 9-10 9-14 10-11 11-12 12-13 13-14 20-25 24-25 27-28 27-32 28-29
29-30 30-31 31-32
isolated ring systems :
containing 9 : 20 : 27 :

G1:O,[*1]

G2:O,CH2,[*2]

G3:C,N

G4:CH3,Et,CN,X,[*3]

Connectivity :

4:2 E exact RC ring/chain

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom
14:Atom 15:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom
25:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 36:CLASS
37:CLASS 38:CLASS 39:CLASS 40:CLASS 42:CLASS

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\ase32.str



chain nodes :
1 2 3 4 8 15 18 36 37 38 39 40 42
ring nodes :
9 10 11 12 13 14 20 21 22 23 24 25 27 28 29 30 31 32
ring/chain nodes :
19
chain bonds :
1-2 2-3 2-8 8-10 14-18 18-19 19-22 37-38 37-39 37-40
ring bonds :
9-10 9-14 10-11 11-12 12-13 13-14 20-21 20-25 21-22 22-23 23-24 24-25 27-28
27-32 28-29 29-30 30-31 31-32
exact/norm bonds :
2-8 8-10 14-18 18-19 19-22 20-21 21-22 22-23 23-24 37-38 37-39 37-40
normalized bonds :
1-2 2-3 9-10 9-14 10-11 11-12 12-13 13-14 20-25 24-25 27-28 27-32 28-29
29-30 30-31 31-32
isolated ring systems :
containing 9 : 20 : 27 :

G1:O,[*1]

G2:O,CH2,[*2]

G3:C,N

G4:CH3,Et,CN,X,[*3]

Connectivity :

4:2 E exact RC ring/chain

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom
14:Atom 15:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom
25:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 36:CLASS
37:CLASS 38:CLASS 39:CLASS 40:CLASS 42:CLASS

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\anjsdfui,str.str





chain nodes :
1 2 3 4 8 15 18 36 37 38 39 40 42
ring nodes :
9 10 11 12 13 14 20 21 22 23 24 25 27 28 29 30 31 32
ring/chain nodes :
19
chain bonds :
1-2 2-3 2-8 8-9 14-18 18-19 19-22 37-38 37-39 37-40
ring bonds :
9-10 9-14 10-11 11-12 12-13 13-14 20-21 20-25 21-22 22-23 23-24 24-25 27-28
27-32 28-29 29-30 30-31 31-32
exact/norm bonds :
2-8 8-9 14-18 18-19 19-22 20-21 21-22 22-23 23-24 37-38 37-39 37-40
normalized bonds :
1-2 2-3 9-10 9-14 10-11 11-12 12-13 13-14 20-25 24-25 27-28 27-32 28-29
29-30 30-31 31-32
isolated ring systems :
containing 9 : 20 : 27 :

G1:O,[*1]

G2:O,CH2,[*2]

G3:C,N

G4:CH3,Et,CN,X,[*3]

Connectivity :

4:2 E exact RC ring/chain

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom
14:Atom 15:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom
25:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 36:CLASS
37:CLASS 38:CLASS 39:CLASS 40:CLASS 42:CLASS

10518679

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

Updated Search

10518679

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 04:03:03 ON 27 SEP 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 04:03:40 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2007 HIGHEST RN 948051-90-9
DICTIONARY FILE UPDATES: 25 SEP 2007 HIGHEST RN 948051-90-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\asdfanjiwer.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 04:09:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5231 TO ITERATE

38.2% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

Updated Search

10518679

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 100283 TO 108957
PROJECTED ANSWERS: 3 TO 324

L2 3 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 04:09:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 104684 TO ITERATE

100.0% PROCESSED 104684 ITERATIONS (1 INCOMPLETE) 150 ANSWERS
SEARCH TIME: 00.00.02

L3 150 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 175.70 175.91

FILE 'HCAPLUS' ENTERED AT 04:09:16 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Sep 2007 VOL 147 ISS 14
FILE LAST UPDATED: 26 Sep 2007 (20070926/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 11 L3

=> s l4 and bell, r?/au
2813 BELL, R?/AU
L5 1 L4 AND BELL, R?/AU

=> d l5, ibib abs hitstr, 1

L5 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

Updated Search

10518679

ACCESSION NUMBER: 2004:2698 HCAPLUS
DOCUMENT NUMBER: 140:59519
TITLE: Preparation of (biphenylylalkoxy)- and [(phenylpyridyl)alkoxy]-substituted phenylalkanoic acids and phenoxyalkanoic acids as hPPAR activators for treatment of cardiovascular disease and related disorders
INVENTOR(S): Hamlett, Christopher Charles Frederick; Bell, Richard; Beswick, Paul John; Gosmini, Romain Luc Marie; King, Nigel Paul; Patel, Vipulkumar Kantibhai
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004000315	A1	20031231	WO 2003-EP6415		20030618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2487909	A1	20031231	CA 2003-2487909		20030618
AU 2003245962	A1	20040106	AU 2003-245962		20030618
EP 1513526	A1	20050316	EP 2003-738056		20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003011931	A	20050405	BR 2003-11931		20030618
CN 1674897	A	20050928	CN 2003-819290		20030618
JP 2005534672	T	20051117	JP 2004-514761		20030618
NZ 537210	A	20060929	NZ 2003-537210		20030618
NO 2004005328	A	20050309	NO 2004-5328		20041203
IN 2004KN01889	A	20060303	IN 2004-KN1889		20041209
ZA 2004010061	A	20060726	ZA 2004-10061		20041213
MX 2004PA12857	A	20050224	MX 2004-PA12857		20041216
US 2006089394	A1	20060427	US 2005-518679		20050816
PRIORITY APPLN. INFO.:			GB 2002-14149	A	20020619
			WO 2003-EP6415	W	20030618

OTHER SOURCE(S): MARPAT 140:59519
GI

Updated Search



I



II

AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = O or (CH2)n; n = 0-2; R3 R4 = independently H, alkyl, OMe, CF3, allyl, or halo; X1 = O, S, SO2, SO, or CH2; R5 and R6 = independently H, (halo)alkyl, or alkoxyalkyl; or CR5R6 = cycloalkyl; R7 = (un)substituted Ph or 6-membered heteroaryl; and pharmaceutically acceptable salts, solvates, and hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators. For example, a mixture of 3-(bromomethyl)-4'-(trifluoromethyl)biphenyl, Et (4-mercapto-2-methylphenoxy)acetate, and polymer-supported diisopropylethylamine in DCM was stirred at room temperature overnight to give the thioether. Saponification of the ester with aqueous NaOH in THF and acidification afforded II. Compds. of the invention showed at least 50% activation of hPPARδ relative to the pos. control at concns. of 10-7 M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, or anorexia nervosa (no data).

IT 638215-24-4P, 3-[2-Methyl-4-[[[4'-(trifluoromethyl)biphenyl-3-yl]methyl]oxy]phenyl]propanoic acid 638215-42-6P, [4-[[1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]acetic acid 638215-46-0P, 3-[4-[[1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638215-68-6P, 4-[4-[[1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]butanoic acid 638216-21-4P, 3-[2-Methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-22-5P, 3-[2-Methyl-4-[[(1S)-1-[6-[4-(methyloxy)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-23-6P, 3-[4-[[(1S)-1-[6-(4-Acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]propanoic acid 638216-24-7P, 3-[4-[[(1S)-1-[6-(4-Cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]propanoic acid 638216-25-8P, 3-[4-[[(1S)-1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]propanoic acid 638216-26-9P, 3-[2-Methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-27-0P, 3-[2-Methyl-4-[[(1R)-1-[6-[4-(methyloxy)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-28-1P,

10518679

3-[4-[[(1R)-1-[6-(4-Acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]propanoic acid 638216-29-2P, 3-[4-[[(1R)-1-[6-(4-Cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]propanoic acid 638216-30-5P, 3-[4-[[(1R)-1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]propanoic acid 638216-31-6P , 3-[3,5-Dimethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-32-7P, 3-[3-(Methyloxy)-5-propyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-33-8P, 3-[3-Propyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-34-9P, 3-[3-(Ethyloxy)-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-35-0P, 3-[4-[[(1R)-1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-36-1P, 3-[3-(Methyloxy)-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-37-2P, [4-[[(1R)-1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]acetic acid 638216-38-3P, [3-Chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]acetic acid 638216-39-4P, [3-(Methyloxy)-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]acetic acid 638216-40-7P, 3-[4-[[(1S)-1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-41-8P, 3-[3-(Methyloxy)-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-42-9P, [4-[[(1S)-1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]acetic acid 638216-43-0P, [3-Chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]acetic acid 638216-44-1P, [3-(Methyloxy)-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]acetic acid 638216-45-2P, 3-[3-Fluoro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-46-3P, 3-[3-Methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-47-4P, 3-[3,5-Bis(methyloxy)-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-48-5P, 3-[2-(Methyloxy)-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-49-6P, 3-[3-Fluoro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-50-9P, 3-[3-Methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-51-0P, 3-[3,5-Bis(methyloxy)-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-52-1P, 3-[2-(Methyloxy)-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-53-2P, 3-[3-Chloro-5-(methyloxy)-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-54-3P, 3-[3-Chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-55-4P, 3-[2-Chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-56-5P, 3-[3-Chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-57-6P, 3-[2-Chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

Updated Search

(Uses)
(hPPAR activator; preparation of (aryloxy)phenylalkanoic acids and (aryloxy)phenoxyalkanoic acids as hPPAR activators for treatment of cardiovascular disease and related disorders)

RN 638215-24-4 HCAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 638215-42-6 HCAPLUS
CN Benzeneacetic acid, 4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638215-46-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638215-68-6 HCAPLUS
CN Benzenebutanoic acid, 4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638216-21-4 HCAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-22-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1S)-1-[6-(4-methoxyphenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-23-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1S)-1-[6-(4-acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-24-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1S)-1-[6-(4-cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-25-8 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1S)-1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-26-9 HCAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-27-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1R)-1-[6-(4-methoxyphenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-28-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1R)-1-[6-(4-acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-29-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1R)-1-[6-(4-cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-30-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1R)-1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-31-6 HCAPLUS
CN Benzenepropanoic acid, 3,5-dimethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638216-32-7 HCAPLUS
CN Benzenepropanoic acid, 3-methoxy-5-propyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638216-33-8 HCAPLUS

Updated Search

CN Benzenepropanoic acid, 3-propyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638216-34-9 HCAPLUS
CN Benzenepropanoic acid, 3-ethoxy-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638216-35-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 638216-36-1 HCAPLUS
CN Benzenepropanoic acid, 3-methoxy-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-37-2 HCAPLUS
CN Benzeneacetic acid, 4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-38-3 HCAPLUS
CN Benzeneacetic acid, 3-chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-39-4 HCAPLUS
CN Benzeneacetic acid, 3-methoxy-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-40-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-41-8 HCAPLUS
CN Benzenepropanoic acid, 3-methoxy-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-42-9 HCAPLUS
CN Benzeneacetic acid, 4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-43-0 HCAPLUS
CN Benzeneacetic acid, 3-chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-44-1 HCAPLUS
CN Benzeneacetic acid, 3-methoxy-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-45-2 HCAPLUS
CN Benzenepropanoic acid, 3-fluoro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-46-3 HCAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-47-4 HCAPLUS
CN Benzenepropanoic acid, 3,5-dimethoxy-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-48-5 HCAPLUS
CN Benzenepropanoic acid, 2-methoxy-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-49-6 HCAPLUS
CN Benzenepropanoic acid, 3-fluoro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-50-9 HCAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-51-0 HCAPLUS
CN Benzenepropanoic acid, 3,5-dimethoxy-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-52-1 HCAPLUS
CN Benzenepropanoic acid, 2-methoxy-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-53-2 HCAPLUS
CN Benzenepropanoic acid, 3-chloro-5-methoxy-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-54-3 HCAPLUS
CN Benzenepropanoic acid, 3-chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-55-4 HCAPLUS
CN Benzenepropanoic acid, 2-chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-56-5 HCAPLUS
CN Benzenepropanoic acid, 3-chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-57-6 HCAPLUS
CN Benzenepropanoic acid, 2-chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 638214-91-2P, (2E)-3-[3,5-Dimethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]-2-propenoic acid
638214-92-3P, (2E)-3-[3-(Methyloxy)-5-(2-propen-1-yl)-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]-2-propenoic acid
638214-93-4P, (2E)-3-[3-(2-Propen-1-yl)-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]-2-propenoic acid
638214-94-5P, (2E)-3-[3-(Ethyloxy)-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]-2-propenoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (aryloxy)phenylalkanoic acids and (aryloxy)phenoxyalkanoic acids as hPPAR activators for treatment of cardiovascular disease and related disorders)

RN 638214-91-2 HCAPLUS
CN 2-Propenoic acid, 3-[3,5-dimethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-

Updated Search

pyridinyl]pentyl]oxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 638214-92-3 HCAPLUS
CN 2-Propenoic acid, 3-[3-methoxy-5-(2-propenyl)-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 638214-93-4 HCAPLUS
CN 2-Propenoic acid, 3-[3-(2-propenyl)-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

Updated Search

10518679



RN 638214-94-5 HCAPLUS
CN 2-Propenoic acid, 3-[3-ethoxy-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 04:03:03 ON 27 SEP 2007)

FILE 'REGISTRY' ENTERED AT 04:03:40 ON 27 SEP 2007
L1 STRUCTURE UPLOADED
L2 3 S L1
L3 150 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 04:09:16 ON 27 SEP 2007
L4 11 S L3
L5 1 S L4 AND BELL, R?/AU

Updated Search

10518679

```
=> s l4 not l5
L6          10 L4 NOT L5

=> s l6 and beswick, p?/au
            58 BESWICK, P?/AU
L7           0 L6 AND BESWICK, P?/AU

=> s l6 and gosmini, r?/au
            17 GOSMINI, R?/AU
L8           0 L6 AND GOSMINI, R?/AU

=> s l6 and grimes, r?/au
           594 GRIMES, R?/AU
L9           0 L6 AND GRIMES, R?/AU

=> s l6 and hamlett, c?/au
             6 HAMLETT, C?/AU
L10          0 L6 AND HAMLETT, C?/AU

=> s l6 and king, n?/au
           621 KING, N?/AU
L11          0 L6 AND KING, N?/AU

=> s l6 and patel, v?/au
          1213 PATEL, V?/AU
L12          0 L6 AND PATEL, V?/AU

=> d l6, ibib abs hitstr, 1-10

L6   ANSWER 1 OF 10  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2006:398359  HCAPLUS
DOCUMENT NUMBER:         145:39840
TITLE:                   1,3,5-Trisubstituted aryls as highly selective
                         PPARδ agonists
AUTHOR(S):               Epple, Robert; Azimioara, Mihai; Russo, Ross;
                         Bursulaya, Badry; Tian, Shin-Shay; Gerken, Andrea;
                         Iskandar, Maya
CORPORATE SOURCE:        Department of Medicinal Chemistry, Genomics Institute
                         of the Novartis Research Foundation, San Diego, CA,
                         92121, USA
SOURCE:                  Bioorganic & Medicinal Chemistry Letters (2006),
                         16(11), 2969-2973
                         CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER:               Elsevier B.V.
DOCUMENT TYPE:           Journal
LANGUAGE:                English
OTHER SOURCE(S):         CASREACT 145:39840
AB   A series of highly potent and selective PPARδ agonists is described
     using the known non-selective ligand GW2433 as a structural template.
     Compound 1 is bioavailable, potent (10 nM), and shows no cross-activity with
     other PPAR subtypes up to 10 μM, making it a useful tool in studying
     the biol. effects of selective PPARδ activation.
IT   870289-57-9P 870289-58-0P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (1,3,5-Trisubstituted aryls as highly selective PPARδ agonists)
RN   870289-57-9  HCAPLUS
CN   Benzeneacetic acid, 4-[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-
```

Updated Search

10518679

5'-yl]methoxy]-3-chloro- (9CI) (CA INDEX NAME)



RN 870289-58-0 HCAPLUS
CN Benzeneacetic acid, 4-[[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methyl]thio]-3-chloro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:101282 HCAPLUS
DOCUMENT NUMBER: 144:184686
TITLE: Remedy for diabetes
INVENTOR(S): Suzuki, Nobuhiro; Suzuki, Masami; Asakawa, Tomoko; Kataoka, Osamu
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006011615	A1	20060202	WO 2005-JP13995	20050726

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,

Updated Search

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2004-218736 A 20040727

OTHER SOURCE(S): MARPAT 144:184686

GI



I

AB A remedy for diabetes with secondary sulfonylurea failure which contains a GPR40 agonist (I; Markush's structure given). Namely, a remedy for diabetes with secondary sulfonylurea failure capable of exerting excellent effects of secreting insulin and lowering the blood glucose level even on diabetic patients on whom sulfonylurea compds. or rapidly acting insulin secretion promoters can exert no insulin secretion effect and thus a sufficient hypoglycemic effect cannot be established.

IT 691902-39-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biphenylylmethoxybenzenepropanoate derivs. as GPR40 agonists and remedies for diabetes with secondary sulfonylurea failure)

RN 691902-39-3 HCAPLUS

CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)methoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1262399 HCAPLUS

DOCUMENT NUMBER: 144:22712

TITLE: Triaryl compounds as PPAR modulators, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Epple, Robert; Azimioara, Mihai

PATENT ASSIGNEE(S): Irm LLC, Bermuda

SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2

Updated Search

10518679

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113506	A1	20051201	WO 2005-US16747	20050513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005245418	A1	20051201	AU 2005-245418	20050513
CA 2564365	A1	20051201	CA 2005-2564365	20050513
EP 1756062	A1	20070228	EP 2005-751010	20050513
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1980894	A	20070613	CN 2005-80019645	20050513
IN 2006CN04198	A	20070615	IN 2006-CN4198	20061114
PRIORITY APPLN. INFO.:			US 2004-571004P P	20040514
			WO 2005-US16747 W	20050513

OTHER SOURCE(S): MARPAT 144:22712
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to aryl compds. of formula I, which are modulators of peroxisome proliferator-activated receptors (PPAR), particularly PPARδ. In compds. I, m is 0-3; X, Y, and Z are independently selected from CH and N; L is (un)substituted (CH2)nO(CH2)n or (CH2)nS(O)p(CH2)n, where each n is independently selected from 0-4 and p is 0-2; R1 and R2 are independently selected from (un)substituted C3-12 cycloalkyl-A-, (un)substituted C3-8 heterocyclyl-A-, (un)substituted C6-10 aryl-A-, and (un)substituted C5-13 heteroaryl-A-, where A is a bond, C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; R3 is selected from halo, C1-6 alkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 haloalkoxy, (un)substituted C6-10 aryl, (un)substituted C5-10 heteroaryl, (un)substituted C3-12 cycloalkyl, and (un)substituted C3-8 heterocyclyl; and R4 is selected from (CH2)nO(CH2)nCO2R5 and (CH2)nCO2R5, where n is as defined previously and R5 is H or C1-6 alkyl; including pharmaceutically acceptable salts, hydrates, solvates, isomers, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a therapeutically effective amount of compound I in combination with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. to treat or prevent diseases or disorders associated with PPAR activity. Substitution of Me bromoacetate with 4-hydroxy-3-methylacetophenone followed by Baeyer-Villiger oxidation and methanolysis gave phenoxyacetate II, which underwent substitution of 3,5-dibromobenzyl

Updated Search

bromide to give dibromobenzyl ether III. Treatment of III with an excess of 4-trifluoromethylphenylboronic acid and ester hydrolysis resulted in the formation of terphenyl IV. Most preferred compds. of the invention express an EC50 value for PPARδ of less than 100 nM. The compds. of the invention are at least 100-fold selective for PPARδ over PPARγ.

IT 870289-57-9P 870289-58-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of triaryl compds. as PPAR modulators and their use for treatment and prevention of diseases associated with PPARδ activity)

RN 870289-57-9 HCAPLUS
CN Benzeneacetic acid, 4-[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-3-chloro- (9CI) (CA INDEX NAME)



RN 870289-58-0 HCAPLUS
CN Benzeneacetic acid, 4-[[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methyl]thio]-3-chloro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1026833 HCAPLUS
DOCUMENT NUMBER: 143:326090
TITLE: Preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivatives for use in treating metabolic

Updated Search

10518679

disorders

INVENTOR(S): Akerman, Michelle; Houze, Jonathan; Lin, Daniel C. H.; Liu, Jiwen; Luo, Jian; Medina, Julio C.; Qiu, Wei; Reagan, Jeffrey D.; Sharma, Rajiv; Shuttleworth, Stephen J.; Sun, Ying; Zhang, Jian; Zhu, Liusheng

PATENT ASSIGNEE(S): Amgen Inc., USA; et al.

SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005086661	A2	20050922	WO 2005-US5815		20050224
WO 2005086661	A3	20060504			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2005220728	A2	20050922	AU 2005-220728		20050224
AU 2005220728	A1	20050922			
CA 2558585	A1	20050922	CA 2005-2558585		20050224
EP 1737809	A2	20070103	EP 2005-723623		20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
CN 1946666	A	20070411	CN 2005-80012709		20050224
BR 2005008098	A	20070717	BR 2005-8098		20050224
JP 2007525516	T	20070906	JP 2007-500959		20050224
US 2006004012	A1	20060105	US 2005-67377		20050225
MX 2006PA09793	A	20061030	MX 2006-PA9793		20060828
US 2007142384	A1	20070621	US 2006-591214		20060828
KR 2007004769	A	20070109	KR 2006-719713		20060922
IN 2006DN05525	A	20070817	IN 2006-DN5525		20060922
NO 2006004362	A	20061122	NO 2006-4362		20060926
PRIORITY APPLN. INFO.:			US 2004-548741P	P	20040227
			US 2004-601579P	P	20040812
			WO 2005-US5815	W	20050224

OTHER SOURCE(S): MARPAT 143:326090

GI

Updated Search



II

AB Title compds. Q-L1-P-L2-M-X-L3-A [Q = H, (hetero)aryl, alkyl, etc.; L1 = bond, alkylene, heteroalkylene, O, etc.; P = (hetero)aromatic, cycloalkylene, etc.; L2 = bond, alkylene, heteroalkylene, etc.; M = (hetero)aromatic, cycloalkylene, arylalkylene, etc.; X = divalent alkyl, (un)substituted-N; O, SO0-2; L3 = bond, alkylene, heteroalkylene, etc.; A = COOH, tetrazolyl, SO3H, PO3H2, etc.; I] are prepared For instance, (S)-3-[4-((4'-trifluoromethyl-1,1'-biphenyl-3-yl)methoxy)phenyl]hexan-4-ynoic acid (II) is prepared in 5 steps from (S)-3-(4-hydroxyphenyl)hexan-4-ynoic acid Me ester (preparation given), 4-(trifluoromethyl)phenylboronic acid and 3-bromobenzoic acid. II has an EC50 < 0.1 μM for human G protein-coupled receptor GPR40. I are useful for the treatment of type II diabetes.

IT 865231-45-4P 865231-46-5P 865231-53-4P
865231-56-7P 865231-57-8P 865231-58-9P
865231-59-0P 865231-64-7P 865232-17-3P
865232-45-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivs. as GPCR40 ligands for use in treating metabolic disorders)

RN 865231-45-4 HCAPLUS

CN Benzenepropanoic acid, β-1-propynyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]-, sodium salt, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 865231-46-5 HCAPLUS

CN Benzenepropanoic acid, β-1-propynyl-4-[[4'-(trifluoromethyl)[1,1'-

Updated Search

biphenyl]-3-yl]methoxy]-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865231-53-4 HCAPLUS
CN Benzenepropanoic acid, β-1-propynyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 865231-56-7 HCAPLUS
CN Benzenepropanoic acid, β-1-propynyl-4-[[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 865231-57-8 HCAPLUS
CN Benzenepropanoic acid, β-1-propynyl-4-[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 865231-58-9 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-chloro-2'-ethoxy[1,1'-biphenyl]-4-yl)methoxy]-β-1-propynyl-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865231-59-0 HCAPLUS
CN Benzenepropanoic acid, 4-[(2'-butoxy-5'-methyl[1,1'-biphenyl]-4-yl)methoxy]-β-1-propynyl-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865231-64-7 HCAPLUS
CN Benzenepropanoic acid, β-1-propynyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 865232-17-3 HCAPLUS

Updated Search

10518679

CN Benzenepropanoic acid, 4-[(2'-butoxy-5'-methyl[1,1'-biphenyl]-4-yl)methoxy]-β-(2-methyl-1-propenyl)-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865232-45-7 HCAPLUS
CN Benzenepropanoic acid, β-[(diethylamino)carbonyl]-β-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



IT 865233-73-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivs. as GPCR40 ligands for use in treating metabolic disorders)
RN 865233-73-4 HCAPLUS
CN Benzeneacetic acid, α-methyl-α-2-propenyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

Updated Search

10518679

ACCESSION NUMBER: 2005:612272 HCAPLUS
DOCUMENT NUMBER: 143:133168
TITLE: A preparation of 3-(4-benzyloxyphenyl)propanoic acid derivatives, useful as GPR40 receptor modulators
INVENTOR(S): Yasuma, Tsuneo; Kitamura, Shuji; Negoro, Nobuyuki
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005063729	A1	20050714	WO 2004-JP19741		20041224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004309271	A1	20050714	AU 2004-309271		20041224
CA 2551610	A1	20050714	CA 2004-2551610		20041224
JP 2006083154	A	20060330	JP 2004-373701		20041224
EP 1697339	A1	20060906	EP 2004-808091		20041224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
CN 1922165	A	20070228	CN 2004-80042139		20041224
BR 2004018148	A	20070417	BR 2004-18148		20041224
MX 2006PA06597	A	20060731	MX 2006-PA6597		20060609
IN 2006KN01749	A	20070511	IN 2006-KN1749		20060622
US 2007149608	A1	20070628	US 2006-584481		20060623
NO 2006003431	A	20060906	NO 2006-3431		20060725
PRIORITY APPLN. INFO.:			JP 2003-431629	A	20031225
			JP 2004-241484	A	20040820
			WO 2004-JP19741	W	20041224

OTHER SOURCE(S): MARPAT 143:133168
GI

Updated Search



I



II

AB The invention relates to a preparation of 3-(4-benzyloxyphenyl)propanoic acid derivs. of formula I [wherein: R1, R3, R4, and R5 are independently H, halogen, or hydrocarbon, etc.; R2 is halogen, NO2, NH2, or hydrocarbon, etc.; R6 and R7 are independently H, halogen, or alkoxy; R8 is H or (un)substituted amino-group; E is a bond, alkylene, or alkylene-O-alkylene, etc.; S is (un)substituted benzene] having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes. The invention compds. showed superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. For instance, 3-(4-benzyloxyphenyl)propanoic acid derivative II (R9 = H; EC50 = 0.01 μM) was prepared via hydrolysis of ester II (R9 = Me) with a yield of 77%.

IT 858096-92-1P 858097-00-4P 858097-32-2P
858097-45-7P 858097-50-4P 858097-72-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 3-(4-benzyloxyphenyl)propanoic acid derivs. useful as GPR40 receptor modulators)

RN 858096-92-1 HCAPLUS

CN Benzenepropanoic acid, 4-[[4'-(2-ethoxyethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-00-4 HCAPLUS

Updated Search

CN Benzenepropanoic acid, 4-[(4'-methoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858097-32-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-ethoxy-1-(ethoxymethyl)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-45-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[3-(6-methyl-2-pyridinyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-50-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-72-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-4-hydroxy-1,1-dioxido-2H-thiopyran-4-yl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)

Updated Search



IT 858096-76-1P 858096-80-7P 858096-84-1P
858096-88-5P 858096-90-9P 858096-95-4P
858096-97-6P 858097-01-5P 858097-03-7P
858097-05-9P 858097-07-1P 858097-09-3P
858097-11-7P 858097-14-0P 858097-16-2P
858097-18-4P 858097-20-8P 858097-22-0P
858097-25-3P 858097-26-4P 858097-35-5P
858097-36-6P 858097-37-7P 858097-38-8P
858097-39-9P 858097-40-2P 858097-42-4P
858097-49-1P 858097-51-5P 858097-52-6P
858097-53-7P 858097-55-9P 858097-58-2P
858097-60-6P 858097-62-8P 858097-64-0P
858097-67-3P 858097-69-5P 858097-74-2P
858097-76-4P 858097-78-6P 858097-80-0P
858097-82-2P 858097-83-3P 858097-86-6P
858097-89-9P 858097-91-3P 858097-92-4P
858097-94-6P 858097-98-0P 858097-99-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-benzyloxyphenyl)propanoic acid derivs. useful as GPR40 receptor modulators)

RN 858096-76-1 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-methoxy-2'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858096-80-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-4'-(1-methylethoxy)[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)

10518679



RN 858096-84-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-4'-[2-(4-methyl-5-thiazolyl)ethoxy][1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858096-88-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-4'-(1-propylbutoxy)[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858096-90-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



Updated Search

10518679

RN 858096-95-4 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[(4'-hydroxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858096-97-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-(1-propylbutoxy)[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-01-5 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-hydroxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858097-03-7 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-chloro-2'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858097-05-9 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-fluoro-2'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)

Updated Search



RN 858097-07-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(2-ethoxyethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-09-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-11-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(cyclopropylmethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-14-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(dimethylamino)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 858097-13-9
CMF C28 H33 N O4

Updated Search



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 858097-16-2 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',4'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858097-18-4 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',4',6'-trimethyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858097-20-8 HCAPLUS
CN Benzenepropanoic acid, 4-[(6-methoxy-2',4'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)

Updated Search

10518679



RN 858097-22-0 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[(2',4',6'-trimethyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858097-25-3 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[[2'-[(4-fluorophenoxy)methyl]-4',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-26-4 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[[4'-[(4-fluorophenoxy)methyl]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-35-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(methoxymethoxy)-2',6'-dimethyl[1,1'-

Updated Search

biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-36-6 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-ethoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858097-37-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(2-butoxyethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-38-8 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[2-(phenylmethoxy)ethoxy][1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Ph

RN 858097-39-9 HCAPLUS

Updated Search

10518679

CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[3-(2-pyridinyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-40-2 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-butoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 858097-42-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(ethylthio)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-49-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-2H-thiopyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-51-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[3-(6-methyl-2-pyridinyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Updated Search

10518679



● HCl

RN 858097-52-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(6-methyl-2-pyridinyl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 858097-53-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[2-(6-methyl-2-pyridinyl)ethoxy][1,1'-biphenyl]-3-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 858097-55-9 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl-4'-nitro[1,1'-biphenyl]-3-yl)methoxy]-2-fluoro- (CA INDEX NAME)

Updated Search



RN 858097-58-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(ethylsulfonyl)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-60-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(diethylamino)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro-, hydrochloride (9CI) (CA INDEX NAME)



RN 858097-62-8 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[3-(2-oxo-1-pyrrolidinyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)

Updated Search

10518679



RN 858097-64-0 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[[4'-(methoxymethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



RN 858097-67-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(acetylethylamino)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-69-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(6-methyl-2-pyridinyl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro-, hydrochloride (9CI) (CA INDEX NAME)

Updated Search



● HCl

RN 858097-74-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(methylsulfonyl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-76-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(3-thienylsulfonyl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-78-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(2-ethoxyethoxy)-6-methoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)

Updated Search



RN 858097-80-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[3'-[[4-(2-carboxyethyl)-3-fluorophenoxy]methyl]-2,6-dimethyl[1,1'-biphenyl]-4-yl]oxy]methyl]-, 1-(1,1-dimethylethyl) ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858097-82-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(6-methyl-2-pyridinyl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-83-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(6-methyl-2-pyridinyl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro-, hydrochloride (9CI) (CA INDEX NAME)

Updated Search



● HCl

RN 858097-86-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-89-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(3-methyl-3-oxetanyl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-91-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-2H-pyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)

Updated Search



RN 858097-92-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-2H-thiopyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-94-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[3-(diethoxyphosphinyl)propoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-98-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-6-(1-methylethoxy)-4'-[(3-methyl-3-oxetanyl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (CA INDEX NAME)



RN 858097-99-1 HCAPLUS

Updated Search

10518679

CN Benzenepropanoic acid, 4-[[4'-[2-(ethylsulfonyl)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:493499 HCAPLUS
DOCUMENT NUMBER: 143:48037
TITLE: Receptor function regulating agent
INVENTOR(S): Fukatsu, Kohji; Fujii, Ryo; Kobayashi, Makoto; Yonemori, Jinichi; Tanaka, Toshio
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 344 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051373	A1	20050609	WO 2004-JP17996	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2547430	A1	20050609	CA 2004-2547430	20041126
EP 1688138	A1	20060809	EP 2004-799921	20041126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

PRIORITY APPLN. INFO.: JP 2003-394848 A 20031126
WO 2004-JP17996 W 20041126

AB A 14273 receptor function regulating agent useful as a preventive/therapeutic agent for diabetes, hyperlipemia, etc. There is provided a 14273 receptor function regulating agent comprising a compound having a group capable of releasing an aromatic ring and a cation.

IT 853010-28-3P 853010-30-7P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

Updated Search

10518679

(receptor function regulating agent)
RN 853010-28-3 HCAPLUS
CN Benzenepropanoic acid, 3,5-difluoro-4-[(4'-methoxy[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



RN 853010-30-7 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-chloro[1,1'-biphenyl]-3-yl)methoxy]-3,5-difluoro- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:96443 HCAPLUS
DOCUMENT NUMBER: 142:176557
TITLE: Preparation of benzoic and phenylacetic acid derivatives as HNF-4α modulators
INVENTOR(S): Mapes, Christopher; Karanewsky, Donald; Thompson, Anthony; Michellys, Pierrre; Ruppar, Daniel; Chen, Jyun-hung
PATENT ASSIGNEE(S): Ligand Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009104	A2	20050203	WO 2004-US23788	20040716
WO 2005009104	A3	20051229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

Updated Search

10518679

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-487915P P 20030716

OTHER SOURCE(S): CASREACT 142:176557; MARPAT 142:176557

GI



I

AB Title compds. I [R1 = H, halo, alkyl, etc.; R2, R4 = H, halo, alkyl, alkenyl, etc.; R3 = H, halo, acyl, Me, etc.; R5 = H, halo, alkyl, alkenyl, etc.; R6 = H, halo, Me, methoxy; R7 = CH2OH, CHO, carboxy, etc.; X, Y = (un)substituted methylene, alkyl, etc.] are prepared For instance, 4-(2-phenylbenzyloxy)phenylacetic acid (II) is prepared from 2-phenylbenzyl bromide and Me 4-hydroxyphenylacetate (DMF, Cs2CO3) and the resulting product converted to the acid (MeOH, THF, H2O, LiOH). II has Ki = 500 nM for the HNF-4α receptor. I are useful for the treatment of, e.g., diabetes, cancer and obesity.

IT 833484-81-4P, 4-[3-(2,4-Difluorophenyl)benzyloxy]phenylacetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoic and phenylacetic acid derivs. as HNF-4α modulators)

RN 833484-81-4 HCAPLUS

CN Benzeneacetic acid, 4-[(2',4'-difluoro[1,1'-biphenyl]-3-yl)methoxy]- (CA INDEX NAME)



L6 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:878169 HCAPLUS

DOCUMENT NUMBER: 141:366218

TITLE: Preparation of substituted (hetero)aromatic compounds that modulate PPAR activity

INVENTOR(S): Bratton, Larry D.; Cheng, Xue-Min; Erasga, Noe; Filzen, Gary F.; Geyer, Andrew G.; Lee, Chitase; Trivedi, Bharat K.; Unangst, Paul C.

PATENT ASSIGNEE(S): Warner Lambert Company LLC, USA

SOURCE: U.S. Pat. Appl. Publ., 90 pp.
CODEN: USXXCO

Updated Search

10518679

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004209936	A1	20041021	US 2004-774260		20040206
US 7244763	B2	20070717			
US 2003225158	A1	20031204	US 2003-347749		20030122
US 6875780	B2	20050405			
CA 2522118	A1	20041028	CA 2004-2522118		20040405
WO 2004091604	A1	20041028	WO 2004-IB1178		20040405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1620086	A1	20060201	EP 2004-725756		20040405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004009486	A	20060502	BR 2004-9486		20040405
JP 2006524220	T	20061026	JP 2006-506486		20040405
NL 1025961	A1	20041026	NL 2004-1025961		20040416
NL 1025961	C2	20050215			
PRIORITY APPLN. INFO.:			US 2003-463641P	P	20030417
			US 2002-370508P	P	20020405
			US 2002-386026P	P	20020605
			WO 2004-IB1178	W	20040405

OTHER SOURCE(S): CASREACT 141:366218; MARPAT 141:366218
GI

Updated Search



I

AB Title compds. I [X0-2 = absent, O, S, amino, etc.; Ar1-2 = (hetero)aryl, etc.; V1 = absent, (un)saturated hydrocarbon chain, etc.; T = (un)saturated, (un)substituted hydrocarbon, etc.; R1-3 = H, alkyl, alkoxy, etc.; R7-8 = H, alkyl, halo, etc.; n = 0-5; q = 0-10; p = 0-10] are prepared For instance, [7-[(4-(4-Chlorophenyl)-4-oxobutyl)sulfanyl]indan-4-yloxy]acetic acid is prepared in 5 steps from 4-hydroxyindan-1-one, Me bromoacetate and 4-chloro-1-(4-chlorophenyl)butan-1-one. Compds. of the invention exhibit IC50 < 9,344 nM for PPARβ and IC50 of < 15,000 nM for PPARα. I are useful for the treatment of dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia.

IT 779187-23-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted (hetero)aromatic compds. that modulate ppar activity for the treatment of, e.g., dyslipidemia)

RN 779187-23-4 HCAPLUS

CN Benzeneacetic acid, 3-methoxy-α,α-dimethyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Updated Search

L6 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:412803 HCAPLUS
DOCUMENT NUMBER: 141:1264
TITLE: Receptor function controlling agent
INVENTOR(S): Fukatsu, Kohji; Sasaki, Shinobu; Hinuma, Shuji; Ito, Yasuaki; Suzuki, Nobuhiro; Harada, Masataka; Yasuma, Tsuneo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 442 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041266	A1	20040521	WO 2003-JP14139	20031106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505322	A1	20040521	CA 2003-2505322	20031106
AU 2003277576	A1	20040607	AU 2003-277576	20031106
JP 2005015461	A	20050120	JP 2003-376833	20031106
EP 1559422	A1	20050803	EP 2003-810621	20031106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1735408	A	20060215	CN 2003-80108260	20031106
PRIORITY APPLN. INFO.:			JP 2002-324632 A	20021108
			JP 2003-16889 A	20030127
			JP 2003-153986 A	20030530
			WO 2003-JP14139 W	20031106

OTHER SOURCE(S): MARPAT 141:1264
AB A GPR40 receptor function controlling agent which contains a compound having an aromatic ring and a group capable of releasing a cation and is useful as a insulin secretion promoting agent or a preventive/remedy for diabetes, etc.
IT 691900-39-7P 691900-43-3P 691902-20-2P
691902-31-5P 691902-33-7P 691902-35-9P
691902-37-1P 691902-39-3P 691902-41-7P
691902-56-4P 691902-57-5P 691902-58-6P
691902-66-6P 691902-68-8P 691902-70-2P
691902-74-6P 691903-11-4P 691903-15-8P
691903-17-0P 691903-19-2P 691903-21-6P
691903-66-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(GPR40 receptor function controlling agents as antidiabetics)
RN 691900-39-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-

yl]methoxy]- (9CI) (CA INDEX NAME)



RN 691900-43-3 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-20-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-(1-methylethyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 691902-31-5 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 691902-33-7 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]-2-fluoro- (9CI) (CA INDEX NAME)

Updated Search



RN 691902-35-9 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]-2-methoxy- (9CI) (CA INDEX NAME)



RN 691902-37-1 HCAPLUS
CN Benzenepropanoic acid, 2-chloro-4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-39-3 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-41-7 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)methoxy]-2-fluoro- (9CI) (CA INDEX NAME)

Updated Search



RN 691902-56-4 HCAPLUS
CN Benzenepropanoic acid, 4-[(2'-methyl-6'-propyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-57-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-6'-(2-methylpropyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 691902-58-6 HCAPLUS
CN Benzenepropanoic acid, 4-[(2'-ethyl-6'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-66-6 HCAPLUS
CN Benzenepropanoic acid, 4-[(2,2',6'-trimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 691902-68-8 HCAPLUS
CN Benzenepropanoic acid, 4-[(6-methoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-70-2 HCAPLUS
CN Benzenepropanoic acid, 4-[(4-methoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-74-6 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 691903-11-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-[(dimethylamino)carbonyl][1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 691903-15-8 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethoxy[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 691903-17-0 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-diethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691903-19-2 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-difluoro[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691903-21-6 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-diethyl[1,1'-biphenyl]-3-yl)methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 691903-66-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-6-(phenylmethoxy)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518679



L6 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:154382 HCAPLUS
DOCUMENT NUMBER: 138:187795
TITLE: Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
INVENTOR(S): Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1009 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016254	A1	20030227	WO 2002-JP8120	20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457468	A1	20030227	CA 2002-2457468	20020808
AU 2002323916	A1	20030303	AU 2002-323916	20020808
EP 1431267	A1	20040623	EP 2002-755874	20020808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011810	A	20040824	BR 2002-11810	20020808
CN 1551866	A	20041201	CN 2002-817376	20020808
HU 200401963	A2	20050128	HU 2004-1963	20020808
NZ 531153	A	20051028	NZ 2002-531153	20020808
NZ 541950	A	20070223	NZ 2002-541950	20020808
ZA 2004000973	A	20050104	ZA 2004-973	20040205
NO 2004000564	A	20040510	NO 2004-564	20040206
MX 2004PA01253	A	20040603	MX 2004-PA1253	20040209
US 2006258728	A1	20061116	US 2004-486220	20040909
PRIORITY APPLN. INFO.:			JP 2001-241867 A	20010809
			WO 2002-JP8120 W	20020808

OTHER SOURCE(S): MARPAT 138:187795
GI

Updated Search



I

AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepared These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisoindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide , (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)p ropenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propana mide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reproduction disorder, and

stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers associated therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, reduction of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation containing (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT 499155-36-1P 499156-67-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499155-36-1 HCAPLUS
CN Benzenepropanoic acid, 4-([1,1'-biphenyl]-4-ylmethoxy)-2-[[[1-(3,5-dimethylphenyl)-3-methylbutyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 499156-67-1 HCAPLUS
CN Benzenepropanoic acid, 2-[[[1-(3,5-dimethylphenyl)-3-methylbutyl]amino]carbonyl]-4-[(4'-propyl[1,1'-biphenyl]-4-yl)methoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 04:03:03 ON 27 SEP 2007)

FILE 'REGISTRY' ENTERED AT 04:03:40 ON 27 SEP 2007
L1 STRUCTURE UPLOADED
L2 3 S L1
L3 150 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 04:09:16 ON 27 SEP 2007
L4 11 S L3
L5 1 S L4 AND BELL, R?/AU
L6 10 S L4 NOT L5
L7 0 S L6 AND BESWICK, P?/AU
L8 0 S L6 AND GOSMINI, R?/AU
L9 0 S L6 AND GRIMES, R?/AU
L10 0 S L6 AND HAMLETT, C?/AU
L11 0 S L6 AND KING, N?/AU
L12 0 S L6 AND PATEL, V?/AU

=> s l3
L13 11 L3

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.77	241.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.58	-8.58

FILE 'CAOLD' ENTERED AT 04:11:15 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3
L14 0 L3

Updated Search

10518679

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.45     242.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -8.58

FILE 'REGISTRY' ENTERED AT 04:11:20 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 SEP 2007  HIGHEST RN 948051-90-9
DICTIONARY FILE UPDATES:  25 SEP 2007  HIGHEST RN 948051-90-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\ase32.str

L15     STRUCTURE UPLOADED

=> d l15
L15 HAS NO ANSWERS
L15             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l15
SAMPLE SEARCH INITIATED 04:12:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     5231 TO ITERATE

 38.2% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**


Updated Search
```

10518679

PROJECTED ITERATIONS: 100283 TO 108957
PROJECTED ANSWERS: 0 TO 0

L16 0 SEA SSS SAM L15

=> s l15 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 04:12:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 104684 TO ITERATE

100.0% PROCESSED 104684 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.02

L17 0 SEA SSS FUL L15

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\anjsdfui,str.str

L18 STRUCTURE UPLOADED

=> d l18
L18 HAS NO ANSWERS
L18 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l18
SAMPLE SEARCH INITIATED 04:13:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5231 TO ITERATE

38.2% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 100283 TO 108957
PROJECTED ANSWERS: 0 TO 0

L19 0 SEA SSS SAM L18

=> s l18 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 04:13:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 104684 TO ITERATE

100.0% PROCESSED 104684 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.03

L20 2 SEA SSS FUL L18

=> d his

Updated Search

10518679

(FILE 'HOME' ENTERED AT 04:03:03 ON 27 SEP 2007)

FILE 'REGISTRY' ENTERED AT 04:03:40 ON 27 SEP 2007
L1 STRUCTURE UPLOADED
L2 3 S L1
L3 150 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 04:09:16 ON 27 SEP 2007
L4 11 S L3
L5 1 S L4 AND BELL, R?/AU
L6 10 S L4 NOT L5
L7 0 S L6 AND BESWICK, P?/AU
L8 0 S L6 AND GOSMINI, R?/AU
L9 0 S L6 AND GRIMES, R?/AU
L10 0 S L6 AND HAMLETT, C?/AU
L11 0 S L6 AND KING, N?/AU
L12 0 S L6 AND PATEL, V?/AU
L13 11 S L3

FILE 'CAOLD' ENTERED AT 04:11:15 ON 27 SEP 2007
L14 0 S L3

FILE 'REGISTRY' ENTERED AT 04:11:20 ON 27 SEP 2007
L15 STRUCTURE UPLOADED
L16 0 S L15
L17 0 S L15 FULL
L18 STRUCTURE UPLOADED
L19 0 S L18
L20 2 S L18 FULL

=> s l20 not l3
L21 2 L20 NOT L3

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	345.55	587.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.58

FILE 'HCAPLUS' ENTERED AT 04:14:06 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Sep 2007 VOL 147 ISS 14

Updated Search

10518679

FILE LAST UPDATED: 26 Sep 2007 (20070926/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l21
L22 1 L21

=> d l22, ibib abs hitstr, 1

L22 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:120834 HCAPLUS
DOCUMENT NUMBER: 140:181466
TITLE: Preparation of resorcinol derivatives as peroxisome proliferator-activated receptor (PPAR) γ-agonists
INVENTOR(S): Shibata, Tomoyuki; Wada, Kunio; Nakamura, Yuji; Araki, Kazushi
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004013109	A1	20040212	WO 2003-JP9834		20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003254795	A1	20040223	AU 2003-254795		20030801
JP 2004123711	A	20040422	JP 2003-205222		20030801
PRIORITY APPLN. INFO.:			JP 2002-225980	A	20020802
			WO 2003-JP9834	W	20030801

OTHER SOURCE(S): MARPAT 140:181466
GI



I

Updated Search

10518679

AB 4-[(Pyrido[2,3-d]imidazol-2-yl or benzimidazol-2-ylalkoxy)phenyl]propanoic acid or acetic acid derivs. represented by the following general formula (I) [wherein X = CH, N; R1 = each (un)substituted C1-6 alkyl, C3-10 cycloalkyl, C2-6 alkenyl, C6-10 aryl, C7-16 aralkyl, 4- to 10-membered heterocycle containing one to three heteroatoms selected from N, O, and S atoms; R2 = each (un)substituted C7-16 aralkyl, C9-16 aralkenyl, or alkyl substituted by a 5- to 10-membered heteroarom. ring containing one to three heteroatoms selected from N, O, and S atoms; R3 = H, C1-6 alkyl, (un)substituted C6-10 aryl; m = 1, 2; n = an integer of 1-3] or pharmacol. acceptable salts or esters thereof are prepared Also disclosed are pharmaceutical compns. containing the compds. I or pharmacol. acceptable salts or esters thereof as the active ingredients (1) for improving insulin-resistance, lowering blood sugar, or inhibiting the proliferation of cancer cells or (2) for the prevention and/or treatment of diabetes, impaired glucose tolerance, obesity, hyperlipemia, or diabetes complications. Thus, 1.09 g 3-(2-benzyloxy-4-hydroxyphenyl)propionic acid Et ester and 697 mg 2-hydroxymethyl-6-methoxy-1-methyl-1H-benzimidazole were dissolved in 30 mL toluene, treated with 1.13 mL tributylphosphine and 1.14 g 1,1'-(azodicarbonyl)dipiperidine and stirred at room temperature overnight to give 87% 3-[2-benzyloxy-4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)phenyl]propionic acid Et ester which (1.5 g) was stirred with a mixture of 7 mL EtOH, 7 mL THF, and 6.3 mL 1 N aqueous NaOH at room temperature overnight and stirred with 1 N aqueous HCl and EtOAc to give 45% 3-[2-benzyloxy-4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)phenyl]propionic acid (II). 3-[4-[2-[6-(4-Amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]ethoxy]-2-(4-chlorobenzyloxy)phenyl]propionic acid hydrochloride was fed t male KK mice with a feed containing 0.01% II for 3 days to lower blood sugar level by 71%. A capsule, a tablet, and a granule containing I were formulated.

IT 657429-45-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of resorcinol derivs. as peroxisome proliferator-activated receptor (PPAR) γ-agonists, anticancer agents, or treatment or prevention of diabetes, impaired glucose tolerance, obesity, or hyperlipemia)

RN 657429-45-3 HCAPLUS

CN Benzenepropanoic acid, 2-([1,1'-biphenyl]-4-ylmethoxy)-4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Updated Search

10518679





● HCl

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.87	595.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-9.36

FILE 'CAOLD' ENTERED AT 04:14:18 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 04:03:03 ON 27 SEP 2007)

FILE 'REGISTRY' ENTERED AT 04:03:40 ON 27 SEP 2007
L1 STRUCTURE UPLOADED
L2 3 S L1

Updated Search

10518679

```
L3          150 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 04:09:16 ON 27 SEP 2007
L4           11 S L3
L5            1 S L4 AND BELL, R?/AU
L6           10 S L4 NOT L5
L7            0 S L6 AND BESWICK, P?/AU
L8            0 S L6 AND GOSMINI, R?/AU
L9            0 S L6 AND GRIMES, R?/AU
L10           0 S L6 AND HAMLETT, C?/AU
L11           0 S L6 AND KING, N?/AU
L12           0 S L6 AND PATEL, V?/AU
L13          11 S L3

     FILE 'CAOLD' ENTERED AT 04:11:15 ON 27 SEP 2007
L14           0 S L3

     FILE 'REGISTRY' ENTERED AT 04:11:20 ON 27 SEP 2007
L15             STRUCTURE UPLOADED
L16           0 S L15
L17           0 S L15 FULL
L18             STRUCTURE UPLOADED
L19           0 S L18
L20           2 S L18 FULL
L21           2 S L20 NOT L3

     FILE 'HCAPLUS' ENTERED AT 04:14:06 ON 27 SEP 2007
L22           1 S L21

     FILE 'CAOLD' ENTERED AT 04:14:18 ON 27 SEP 2007

=> s l21
L23           0 L21

=> s l3
L24           0 L3
```

Updated Search